Exact Mass: 425.2354666

D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists C78272 - Agent Affecting Nervous System > C681 - Opiate Antagonist Same as: D07863

Nafoxidine

1-{2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine

C29H31NO2 (425.2354666)

D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C1971 - Angiogenesis Activator Inhibitor C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent

LysoPE(14:0/0:0)

(2-aminoethoxy)[(2R)-2-hydroxy-3-(tetradecanoyloxy)propoxy]phosphinic acid

LysoPE(14:0/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(14:0/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.

LysoPE(0:0/14:0)

(2-aminoethoxy)[(2R)-3-hydroxy-2-(tetradecanoyloxy)propoxy]phosphinic acid

LysoPE(0:0/14:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/14:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.

O-Desmethyltramadol glucuronide

(2S,3S,4S,5R,6S)-6-{3-[(1R,2R)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenoxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C21H31NO8 (425.2049566)

O-Desmethyltramadol glucuronide is a metabolite of tramadol. Tramadol hydrochloride (trademarked as Conzip, Ryzolt, Ultracet, Ultram in the USA; Ralivia and Zytram XL in Canada) is a centrally-acting synthetic analgesic used to treat moderate to moderately-severe pain. The drug has a wide range of applications, including treatment of rheumatoid arthritis, restless legs syndrome, and fibromyalgia. It was launched and marketed as Tramal by the German pharmaceutical company Grnenthal GmbH in 1977 (Wikipedia).

M2 di-hydroxylated metabolite

2-(1-{1-[2-(2-fluorophenyl)ethyl]piperidin-4-yl}-4-hydroxy-1H-indol-6-yl)-2-hydroxy-N-methylethanimidic acid

C24H28FN3O3 (425.211459)

M2 di-hydroxylated metabolite is a metabolite of saquinavir. Saquinavir is an antiretroviral drug used in HIV therapy. It falls in the protease inhibitor class. Two formulations have been marketed: a hard-gel capsule formulation of the mesylate, with trade name Invirase, which requires combination with ritonavir to increase the saquinavir bioavailability; a soft-gel capsule formulation of saquinavir, with trade name Fortovase. Both formulations are generally used as a component of highly active antiretroviral therapy (HAART). (Wikipedia)

N,O-Didesmethylvenlafaxine glucuronide

(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-{4-[1-(1-hydroxycyclohexyl)-2-(methylamino)ethyl]phenoxy}oxane-2-carboxylic acid

C21H31NO8 (425.2049566)

N,O-Didesmethylvenlafaxine glucuronide is a metabolite of venlafaxine (brand name: Effexor or Efexor). Venlafaxine is a bicyclic antidepressant and is usually categorized as a serotonin-norepinephrine reuptake inhibitor (SNRI), but it has been referred to as a serotonin-norepinephrine-dopamine reuptake inhibitor. It works by blocking the transporter reuptake proteins for key neurotransmitters affecting mood, thereby leaving more active neurotransmitters in the synapse.

(6Z,8Z)-Hexadeca-6,8-dienedioylcarnitine

3-[(15-carboxypentadeca-6,8-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

(6Z,8Z)-Hexadeca-6,8-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (6Z,8Z)-hexadeca-6,8-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z,8Z)-Hexadeca-6,8-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6Z,8Z)-Hexadeca-6,8-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(4E,6Z)-Hexadeca-4,6-dienedioylcarnitine

3-[(15-carboxypentadeca-4,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

(4E,6Z)-Hexadeca-4,6-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (4E,6Z)-hexadeca-4,6-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,6Z)-Hexadeca-4,6-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (4E,6Z)-Hexadeca-4,6-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(6E,9E)-Hexadeca-6,9-dienedioylcarnitine

3-[(15-carboxypentadeca-6,9-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

(6E,9E)-Hexadeca-6,9-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (6E,9E)-hexadeca-6,9-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6E,9E)-Hexadeca-6,9-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6E,9E)-Hexadeca-6,9-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(7Z,13Z)-hexadeca-7,13-dienedioylcarnitine

3-[(15-carboxypentadeca-7,13-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

(7Z,13Z)-Hexadeca-7,13-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (7Z,13Z)-hexadeca-7,13-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7Z,13Z)-Hexadeca-7,13-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (7Z,13Z)-Hexadeca-7,13-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(4Z,7Z)-Hexadeca-4,7-dienedioylcarnitine

3-[(15-carboxypentadeca-4,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

(4Z,7Z)-Hexadeca-4,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z)-hexadeca-4,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z)-Hexadeca-4,7-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (4Z,7Z)-Hexadeca-4,7-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(12E,14E)-hexadeca-12,14-dienedioylcarnitine

3-[(15-carboxypentadeca-12,14-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C21H27N7O3 (425.21752720000006)

(12E,14E)-Hexadeca-12,14-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (12E,14Z)-hexadeca-12,14-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (12E,14E)-Hexadeca-12,14-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (12E,14E)-Hexadeca-12,14-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol

4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]but-3-yn-1-ol

C27H24FN3O (425.1903306)

(S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol

2-Azetidinecarboxylic acid, 3-(3-((aminoiminomethyl)amino)propyl)-1-((4-(((1,1-dimethylethyl)amino)carbonyl)-1-piperazinyl)carbonyl)-4-oxo-, (2S,3R)-

Diprenorphine

3-(cyclopropylmethyl)-16-(2-hydroxypropan-2-yl)-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7,9,11-trien-11-ol

Gly-pro-arg-pro

1-(2-{[1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}-5-[(diaminomethylidene)amino]pentanoyl)pyrrolidine-2-carboxylic acid

C22H27N5O4 (425.20629420000006)

Guanidine, N-((2S,3S,4R)-6-amino-2-(dimethoxymethyl)-3,4-dihydro-3-hydroxy-2-methyl-2H-1-benzopyran-4-yl)-N'-cyano-N'-(phenylmethyl)-

Guanidine, N-((2S,3S,4R)-6-amino-2-(dimethoxymethyl)-3,4-dihydro-3-hydroxy-2-methyl-2H-1-benzopyran-4-yl)-N-cyano-N-(phenylmethyl)-

Losoxantrone

6-hydroxy-14-{2-[(2-hydroxyethyl)amino]ethyl}-10-({2-[(2-hydroxyethyl)amino]ethyl}amino)-14,15-diazatetracyclo[7.6.1.0^{2,7}.0^{13,16}]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one

C22H27N5O4 (425.20629420000006)

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D000970 - Antineoplastic Agents

Piriprost

5-[5-hydroxy-4-(3-hydroxyoct-1-en-1-yl)-1-phenyl-1H,4H,5H,6H-cyclopenta[b]pyrrol-2-yl]pentanoic acid

C21H32ClN3O4 (425.20812220000005)

Revexepride

4-Amino-5-chloro-N-{[3-hydroxy-1-(3-methoxypropyl)piperidin-4-yl]methyl}-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboximidate

Prostaglandin D2 serinol amide

N-[(2-hydroxy-1-hydroxymethyl)ethyl]-11-oxo-9α,15S-dihydroxy-prosta-5Z,13E-dien-1-amide

histidylasparagylarginine

Tyr-Pro-Phe

Tyr Ile Met

Prostaglandin E2 serinol amide

N-[(2-hydroxy-1-hydroxymethyl)ethyl]-9-oxo-11α,15S-dihydroxy-prosta-5Z,13E-dien-1-amide

Tyr Met Ile

His Arg Asn

Met Tyr Ile

Ile Tyr Met

Phe Ile Phe

asparagylhistidylarginine

Arg Asn His

Arg His Asn

Pro Tyr Phe

Met Ile Tyr

1-tetradecanoyl-sn-glycero-3-phosphoethanolamine

1-Myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine

Ala Ala His Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-3-(1H-imidazol-4-yl)propanamido]hexanoic acid

Ala Ala His Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-3-(1H-imidazol-4-yl)propanamido]-4-carbamoylbutanoic acid

Ala Ala Lys His

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]hexanamido]-3-(1H-imidazol-4-yl)propanoic acid

Ala Ala Gln His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-4-carbamoylbutanamido]-3-(1H-imidazol-4-yl)propanoic acid

Ala His Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]propanamido]hexanoic acid

Ala His Ala Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]propanamido]-4-carbamoylbutanoic acid

Ala His Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]hexanamido]propanoic acid

Ala His Gln Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]-4-carbamoylbutanamido]propanoic acid

Ala Lys Ala His

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]propanamido]-3-(1H-imidazol-4-yl)propanoic acid

Ala Lys His Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-3-(1H-imidazol-4-yl)propanamido]propanoic acid

Ala Gln Ala His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-4-carbamoylbutanamido]propanamido]-3-(1H-imidazol-4-yl)propanoic acid

Ala Gln His Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-4-carbamoylbutanamido]-3-(1H-imidazol-4-yl)propanamido]propanoic acid

Gly Gly His Arg

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanoic acid

Gly Gly Arg His

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanoic acid

Gly His Gly Arg

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]acetamido}-5-carbamimidamidopentanoic acid

Gly His Asn Val

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]-3-methylbutanoic acid

Gly His Arg Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanamido]acetic acid

Gly His Val Asn

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]-3-carbamoylpropanoic acid

Gly Asn His Val

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanoic acid

Gly Asn Val His

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanoic acid

Gly Pro Pro Arg

(2S)-2-{[(2S)-1-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoic acid

Gly Pro Arg Pro

(2S)-1-[(2S)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoyl]pyrrolidine-2-carboxylic acid

Gly Arg Gly His

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]acetamido}-3-(1H-imidazol-4-yl)propanoic acid

Gly Arg His Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanamido]acetic acid

Gly Arg Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

Gly Val His Asn

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanoic acid

Gly Val Asn His

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanoic acid

His Ala Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]propanamido]propanamido]hexanoic acid

His Ala Ala Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]propanamido]propanamido]-4-carbamoylbutanoic acid

His Ala Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]propanamido]hexanamido]propanoic acid

His Ala Gln Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]propanamido]-4-carbamoylbutanamido]propanoic acid

His Gly Gly Arg

(2S)-2-(2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}acetamido)-5-carbamimidamidopentanoic acid

His Gly Asn Val

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}-3-carbamoylpropanamido]-3-methylbutanoic acid

His Gly Arg Gly

2-[(2S)-2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}-5-carbamimidamidopentanamido]acetic acid

His Gly Val Asn

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}-3-methylbutanamido]-3-carbamoylpropanoic acid

His Lys Ala Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]hexanamido]propanamido]propanoic acid

His Asn Gly Val

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]acetamido}-3-methylbutanoic acid

His Asn Val Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]-3-methylbutanamido]acetic acid

His Gln Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-4-carbamoylbutanamido]propanamido]propanoic acid

Tyr Phe Pro

His Arg Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanamido]acetamido}acetic acid

His Val Gly Asn

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]acetamido}-3-carbamoylpropanoic acid

His Val Asn Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]-3-carbamoylpropanamido]acetic acid

Leu Tyr Met

Leu Phe Phe

Lys Ala Ala His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]propanamido]-3-(1H-imidazol-4-yl)propanoic acid

Lys Ala His Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]-3-(1H-imidazol-4-yl)propanamido]propanoic acid

Tyr Leu Met

Lys His Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-imidazol-4-yl)propanamido]propanamido]propanoic acid

Met Tyr Leu

Ile Met Tyr

Phe Tyr Pro

Met Ile Tyr

Asn His Arg

Ile Tyr Met

Asn Gly His Val

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanoic acid

Asn Gly Val His

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanoic acid

Asn His Gly Val

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]acetamido}-3-methylbutanoic acid

Asn His Val Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]acetic acid

Phe Phe Leu

Asn Pro Pro Val

(2S)-2-{[(2S)-1-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-3-methylbutanoic acid

Asn Pro Val Pro

(2S)-1-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-3-methylbutanoyl]pyrrolidine-2-carboxylic acid

Met Tyr Ile

Asn Val Gly His

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-methylbutanamido]acetamido}-3-(1H-imidazol-4-yl)propanoic acid

Asn Val His Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanamido]acetic acid

Asn Val Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-methylbutanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

Tyr Met Leu

Pro Gly Pro Arg

(2S)-5-carbamimidamido-2-{[(2S)-1-{2-[(2S)-pyrrolidin-2-ylformamido]acetyl}pyrrolidin-2-yl]formamido}pentanoic acid

Pro Gly Arg Pro

(2S)-1-[(2S)-5-carbamimidamido-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}pentanoyl]pyrrolidine-2-carboxylic acid

Pro Asn Pro Val

(2S)-2-{[(2S)-1-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanoyl]pyrrolidin-2-yl]formamido}-3-methylbutanoic acid

Pro Asn Val Pro

(2S)-1-[(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid

Pro Pro Gly Arg

(2S)-5-carbamimidamido-2-(2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}acetamido)pentanoic acid

Phe Leu Phe

Pro Pro Asn Val

(2S)-2-[(2S)-3-carbamoyl-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}propanamido]-3-methylbutanoic acid

Pro Pro Arg Gly

2-[(2S)-5-carbamimidamido-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}pentanamido]acetic acid

Pro Pro Val Asn

(2S)-3-carbamoyl-2-[(2S)-3-methyl-2-{[(2S)-1-{[(2S)-pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}butanamido]propanoic acid

Pro Arg Gly Pro

(2S)-1-{2-[(2S)-5-carbamimidamido-2-[(2S)-pyrrolidin-2-ylformamido]pentanamido]acetyl}pyrrolidine-2-carboxylic acid

Pro Arg Pro Gly

2-{[(2S)-1-[(2S)-5-carbamimidamido-2-[(2S)-pyrrolidin-2-ylformamido]pentanoyl]pyrrolidin-2-yl]formamido}acetic acid

Pro Val Asn Pro

(2S)-1-[(2S)-3-carbamoyl-2-[(2S)-3-methyl-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]propanoyl]pyrrolidine-2-carboxylic acid

Pro Val Pro Asn

(2S)-3-carbamoyl-2-{[(2S)-1-[(2S)-3-methyl-2-[(2S)-pyrrolidin-2-ylformamido]butanoyl]pyrrolidin-2-yl]formamido}propanoic acid

Gln Ala Ala His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]propanamido]propanamido]-3-(1H-imidazol-4-yl)propanoic acid

Gln Ala His Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]propanamido]-3-(1H-imidazol-4-yl)propanamido]propanoic acid

Leu Met Tyr

Tyr Pro Phe

Gln His Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-(1H-imidazol-4-yl)propanamido]propanamido]propanoic acid

Tyr Ile Met

Arg Gly Gly His

(2S)-2-(2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}acetamido)-3-(1H-imidazol-4-yl)propanoic acid

Arg Gly His Gly

2-[(2S)-2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}-3-(1H-imidazol-4-yl)propanamido]acetic acid

Arg Gly Pro Pro

(2S)-1-{[(2S)-1-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetyl}pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

Arg His Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanamido]acetamido}acetic acid

Met Leu Tyr

Arg Pro Gly Pro

(2S)-1-(2-{[(2S)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}acetyl)pyrrolidine-2-carboxylic acid

Arg Pro Pro Gly

2-{[(2S)-1-{[(2S)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}acetic acid

Tyr Met Ile

His Asn Arg

Phe Phe Ile

Val Gly His Asn

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanoic acid

Val Gly Asn His

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanoic acid

Val His Gly Asn

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanamido]acetamido}-3-carbamoylpropanoic acid

Val His Asn Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]acetic acid

Val Asn Gly His

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-carbamoylpropanamido]acetamido}-3-(1H-imidazol-4-yl)propanoic acid

Val Asn His Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]acetic acid

Val Asn Pro Pro

(2S)-1-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-carbamoylpropanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidine-2-carboxylic acid

Val Pro Asn Pro

(2S)-1-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

Val Pro Pro Asn

(2S)-2-{[(2S)-1-{[(2S)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]carbonyl}pyrrolidin-2-yl]formamido}-3-carbamoylpropanoic acid

C18H36NO8P (425.21784260000004)

Divaleroylphosphatidylcholine

3,5,9-Trioxa-4-phosphatetradecan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxopentyl)oxy]-, inner salt, 4-oxide, (R)-

PC(5:0/5:0)[U]

3,5,9-Trioxa-4-phosphatetradecan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxopentyl)oxy]-, inner salt, 4-oxide

C18H36NO8P (425.21784260000004)

PC(11:0/0:0)

Undecanoin, 1-mono-, 3-(dihydrogen phosphate), monoester with choline hydroxide inner salt, L-

PC(11:0/0:0)[U]

3,5,9-Trioxa-4-phosphaeicosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide

PC(0:0/11:0)[U]

3,5,8-Trioxa-4-phosphanonadecan-1-aminium, 4-hydroxy-7-(hydroxymethyl)-N,N,N-trimethyl-9-oxo-, inner salt, 4-oxide

PE(14:0/0:0)

Tetradecanoic acid, 3-[[(2-aminoethoxy)hydroxyphosphinyl]oxy]-2-hydroxypropyl ester, (R)-

LPE(14:0)

1-Hydroxy-2-myristoyl-sn-glycero-3-phosphoethanolamine

PGD2-dihydroxypropanylamine

N-(1,3-dihydroxypropan-2-yl)-9S,15S-dihydroxy-11-oxo-5Z,13E-prostadienoyl amine

PGE2-dihydroxypropanylamine

N-(1,3-dihydroxypropan-2-yl)-9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoyl amine

C18H36NO8P (425.21784260000004)

PC 10:0

1,2-divaleryl-sn-glycero-3-phosphocholine

LPC 11:0

1-undecanoyl-sn-glycero-3-phosphocholine

LPE 14:0

Tetradecanoic acid, 3-[[(2-aminoethoxy)hydroxyphosphinyl]oxy]-2-hydroxypropyl ester, (R)-

SCH 563705

C21H40NNaO4S (425.2575600000001)

sodium 2-[methyloleoylamino]ethane-1-sulphonate

2-(4,6-Diphenyl-1,3,5-triazin-2-yl)-5-[(hexyl)oxy]-phenol

C27H27N3O2 (425.2103162)

Piriprost

5-[5-hydroxy-4-[(E)-3-hydroxyoct-1-enyl]-1-phenyl-5,6-dihydro-4H-cyclopenta[b]pyrrol-2-yl]pentanoic acid

C21H27N7O3 (425.21752720000006)

D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors C471 - Enzyme Inhibitor > C1322 - Lipooxygenase Inhibitor C78568 - Prostaglandin Analogue

(S)-BnCH2-PyBox, (S,S)-2,6-Bis(4-benzylmethyl-2-oxazolin-2-yl)pyridine

C27H27N3O2 (425.2103162)

GSK690693

(S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C155764 - AKT Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation[1][2][3]. GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation[1][2][3].

2-(((3-(Aziridin-1-yl)propanoyl)oxy)methyl)-2-ethylpropane-1,3-diyl bis(3-(aziridin-1-yl)propanoate)

C21H35N3O6 (425.25257300000004)

GPRP